Company Description
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States.
The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer.
It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment.
Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Thomas Jensen |
Contact Details
Address: 123 E. Tarpon Ave. Tarpon Springs, Florida 34689 United States | |
| Phone | 401 426 4664 |
| Website | allarity.com |
Stock Details
| Ticker Symbol | ALLR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $0.00 |
| CIK Code | 1860657 |
| CUSIP Number | 016744500 |
| ISIN Number | US0167445008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas H. Jensen | Founder, Chief Executive Officer and Director |
| Dr. Jeremy R. Graff Ph.D. | President and Chief Development Officer |
| Dr. Steen Meier Knudsen Ph.D. | Founder and Chief Scientific Officer |
| Jeffrey S. Ervin M.B.A. | Chief Financial Officer |
| Dr. Jose L. Iglesias M.D. | Consultant Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 16, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Jul 1, 2026 | 8-K | Current Report |
| Jun 22, 2026 | 8-K | Current Report |
| Jun 2, 2026 | 8-K | Current Report |
| May 15, 2026 | 10-Q | Quarterly Report |
| May 8, 2026 | 8-K | Current Report |
| May 6, 2026 | 8-K | Current Report |